Pimagedine targeting TIMP3 acts as an inhibitor of advanced glycation end products and is effective in managing diabetic nephropathy when used on its own or in conjunction with other treatments (Corbett et al., 1992). This evidence concerns the gene TIMP3 and diabetic kidney disease.